2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5799 External validation of the absolute lymphocyte count threshold and evaluation of candidate risk scores for delayed neurotoxicity after ciltacabtagene autoleucel — an international myeloma working group (IMWG) immunotherapy registry study

Susan Bal, MD, Eric Matthew Jurgens, MD2, Chiung-Yu Huang, PhD3, Sireesha Asoori, MBBS, MPH4, Torsten Steinbrunn, MD, PhD5, Christine Riedhammer6, Florian Eisele7, Hermann Einsele, MD, PhD8, Carlyn Rose Tan, MD9, Saad Z. Usmani, MD10, priyanka venkatesh, MD11, Luciano J. Costa, MD, PhD12, Michael Rosenzweig, MD13, Myo Htut, MD14, Mrugakshi Dave, MS15, Joaquin Martinez-Lopez Sr, MD, PhD16, Alberto Blanco, MD17, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD18, Kate Milne19, Efstathios Kastritis, MD20, Meletios-Athanasios (Thanos) C. Dimopoulos, MD21, Melinda Tan, MD22, Hira Mian, MD23, Chandramouli Nagarajan, MD, MBBS, FRCP, FRCPath24, Wee-Joo Chng Jr, MD, PhD, MBBS, FRCP, FRCPath25, Allison Tso26, Juan Du, MD, PhD27, Roman Hajek, MD, PhD28, Laurent Garderet29, Kihyun Kim, MD, PhD30, Paula Rodriguez Otero, MD, PhD31, Yi Lin Jr, MD, PhD32, Thomas Martin, MD33
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 University of San Francisco, San Francisco, California, United States
4 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
5 University Hospital Würzburg, Würzburg, Germany
6 University Hospital Würzburg, Würzburg, Germany
7 University Hospital Würzburg, Würzburg, Germany
8 University Hospital Würzburg, Würzburg, Germany
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 University of Alabama at Birmingham, Birmingham, Alabama, United States
12 University of Alabama at Birmingham, Birmingham, Alabama, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 International Myeloma Foundation, Studio City, California, United States
16 Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain
17 Hospital Universitario 12 De Octubre, Madrid, Spain
18 The London Hospital Medical College, London, United Kingdom
19 The London Hospital Medical College, London, United Kingdom
20 National and Kapodistrian University of Athens, Athens, Greece
21 National and Kapodistrian University of Athens, Athens, Greece
22 Mayo Clinic, Rochester, Minnesota, United States
23 McMaster University, Hamilton, Ontario, Canada
24 Singapore General Hospital and National Cancer Centre, Singapore, Singapore
25 National University Cancer Institute, Singapore, Singapore
26 Tan Tock Seng Hospital, Singapore, Singapore
27 Shanghai Renji Hospital, Shanghai, China
28 University of Ostrava, Ostrava, Czech Republic
29 Hôpital Universitaire de la Pitié-Salpêtrière, Paris, France
30 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Rep. of South
31 Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA,, Pamplona, Spain
32 Mayo Clinic, Rochester, Minnesota, United States
33 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Background: Delayed immune effector cell-associated neurotoxicity [nerve palsy (IEC-NP) and Parkinsonism (IEC-PKS)] is a recognized late complication of BCMA directed CART therapy, including ciltacabtagene autoleucel (cilta-cel) in relapsed and refractory multiple myeloma (RRMM). Early data suggests that peak absolute lymphocyte count (ALCₚₑₐₖ) ≥3×10⁹/L post-infusion may predict delayed neurotoxicity. We performed a multicenter external validation and recalibration of this ALC threshold and evaluated potential risk scores incorporating additional clinical predictors.

Methods: We analyzed consecutive patients with RRMM who received commercial cilta-cel across IMWG centers with complete outcome information for delayed neurotoxicity. ALCₚₑₐₖ within 30 days of CART cell infusion was assessed both continuously and dichotomized at the published 3×10⁹/L threshold. Candidate predictors were screened by Mann-Whitney U or Fisher's exact test; variables significant at P<.10 were eligible for multivariable modeling. We intended to test the performance of identified risk factors as predictors of delayed neurotoxicity.

Results: In an independent international cohort of 514 consecutive patients who received cilta-cel, we identified 361 patients who formed the analytic cohort based on complete data availability. Among the 361 patients, median age was 64 years (9% were older than 75); 60% were male, 78% White, 12% Black, 30% had ISS stage 3, 21% had R-ISS stage 3, 52% had triple-class refractory RRMM, 24% had iFLC >20 mg/dL, median number of prior lines of therapy was 4 (44% had received 1–3 prior lines, 56% had received ≥4). Following infusion, 73% developed CRS (16% grade ≥2), and 8% developed ICANS.

Within the 361 patients, 41 (11%) developed delayed neurotoxicity (IEC-NP n=34, IEC-PKS n=11, both n=4). ALCₚₑₐₖ ≥3×10⁹/L within 30 days of cilta-cel infusion was strongly associated with delayed neurotoxicity (OR 7.57, 95% CI 3.68–16.84; sensitivity 75.6%, specificity 70.9%, PPV 25.0%, NPV 95.8%; P<.001). ALCₚₑₐₖ ≥3×10⁹/L was strongly associated with IEC-NP (OR 8.22, 95% CI 3.79–19.84; sensitivity 76.5%, specificity 71.7%, PPV 16.0%, NPV 97.7%; P<.001). ALCₚₑₐₖ ≥3×10⁹/L was strongly associated with IEC-PKS (OR 10.29, 95% CI 2.61–68.04; sensitivity 81.8%, specificity 69.6%, PPV 5.6%, NPV 99.4%; P=.003).

Our optimal cutpoint identified using Youden’s index (3.25×10⁹/L; AUC 0.749, 95% CI 0.672–0.825) closely approximates the published threshold. Among candidate variables screened, ALCₚₑₐₖ, age, sex, CAR T-cell line of therapy, and any-grade CRS were significant at P<.10 on univariate testing and were entered into multivariable modeling. In the multivariable model, ALCₚₑₐₖ≥3 (adjusted OR 4.90, 95% CI 2.31–11.19), any-grade CRS (OR 8.25, 95% CI 1.66–149.95), earlier CAR T-cell line of therapy (≤4 vs ≥5; OR 2.39, 95% CI 1.17–5.08), and male sex (OR 2.39, 95% CI 1.10–5.65) were significantly associated with delayed neurotoxicity while age >75 years was not significant (OR 2.32, 95% CI 0.82–6.18; P=.10). This multivariable model improved discrimination over ALCₚₑₐₖ ≥3×10⁹/L alone (AUC 0.813 vs. 0.721; DeLong's test P=0.0008).

We evaluated candidate point-based risk scores using the same predictors and compared them to ALCₚₑₐₖ ≥3×10⁹/L alone, but none of the composite risk scores (equal weight additive score, different weighted scores) outperformed ALCₚₑₐₖ ≥3×10⁹/L alone at their optimal cut-offs (AUC 0.678-0.690 vs. 0.733) with 95.8% NPV for ALCₚₑₐₖ ≥3×10⁹/L alone.

Conclusion: ALCₚₑₐₖ ≥3×10⁹/L is externally validated as a robust predictor of delayed neurotoxicity after cilta-cel. A multivariable model incorporating CRS, line of therapy and sex improves discrimination over ALCpeak alone, but this benefit was not captured using simple integer-weighted risk scores. Our findings support the ALCₚₑₐₖ <3×10⁹/L threshold as a practical bedside tool for ruling out delayed neurotoxicity, particularly IEC-PKS. It may also identify patients with ALCₚₑₐₖ ≥3×10⁹/L at risk for delayed neurotoxicity warranting additional neurologic surveillance and potential intervention.

Susan Bal, MD: AstraZeneca - Honoraria; Amyloid Foundation - Honoraria; MJH Life Sciences - Honoraria; Pfizer - Honoraria; Bristol Myers Squibb/Celgene - Honoraria; Johnson & Johnson - Honoraria; BeiGene - Honoraria; Fate Therapeutics - Honoraria; Bristol Myers Squibb Foundation - Honoraria; Adaptive Biotechnologies, - Honoraria; AbbVie - Honoraria; Kite/Arcellx - Honoraria; Amyloid Foundation - Research Funding; BeiGene - Research Funding; Bristol Myers Squibb Foundation - Research Funding; Johnson & Johnson - Research Funding; MJH Life Sciences - Research Funding; AstraZeneca - Research Funding; Adaptive Biotechnologies, - Research Funding; Kite/Arcellx - Research Funding; AbbVie - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Pfizer - Research Funding; Fate Therapeutics - Research Funding; GSK - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Amyloid Foundation - Consultancy (Includes expert testimony); MJH Life Sciences - Consultancy (Includes expert testimony); Adaptive Biotechnologies, - Consultancy (Includes expert testimony); Kite/Arcellx - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Bristol Myers Squibb Foundation - Consultancy (Includes expert testimony)